title: Respiratory responses to progesterone and allopregnanolone following chronic caffeine treatment in newborn female rats.
abstract: We recently showed that in 12-day-old male rats exposed to caffeine for 10 consecutive days, progesterone inhibits the respiratory response to hypoxia and increases apnea frequency (Uppari et al., 2016). This was partly due to a higher inhibitory response of GABAa receptor to allopregnanolone, the neuroactive metabolite of progesterone. In the present study, we addressed whether similar effects occur in females. We used newborn female rats daily gavaged with water (control) or caffeine (15mg/kg) between the postnatal (P) days 3-12. At P12, we recorded ventilation, metabolic rate, and apnea frequency and duration in normoxia and in response to moderate hypoxia, following an intraperitonial injection of progesterone (4mg/kg) or allopregnanolone (10mg/kg). In control rats, progesterone had no effect on breathing in normoxia and in hypoxia, and in rats treated with caffeine it decreased the initial increase in respiratory frequency in hypoxia. In both groups, allopregnalone decreased breathing frequency in normoxia and in hypoxia and increased the frequency of apnea in normoxia in control rats and in rats treated with caffeine. Injection of bicuculline (a specific GABAa receptor antagonist) prevented the inhibitory effects of allopregnanolone on breathing in both groups. These data indicate that chronic caffeine treatment unmasked an inhibitory effect of progesterone on the hypoxic response but this was weaker than in males, and contrasting to what was observed in male rats (Uppari et al., 2016), GABAa receptors are not significantly affected by chronic caffeine treatment in newborn female rats.
authors.affiliation: Centre de Recherche de l'Institut Universitaire, de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.
authors.forename: Naga Praveena
authors.initials: NP
authors.lastname: Uppari
authors.affiliation: Centre de Recherche de l'Institut Universitaire, de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.
authors.forename: Vincent
authors.initials: V
authors.lastname: Joseph
authors.affiliation: Centre de Recherche de l'Institut Universitaire, de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada. Electronic address: Aida.Bairam@crchudequebec.ulaval.ca.
authors.forename: Aida
authors.initials: A
authors.lastname: Bairam
mesh_terms: D000704:Analysis of Variance; D000777:Anesthetics / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001049:Apnea / Q000503:physiopathology; D002110:Caffeine / Q000008:administration & dosage*; D002245:Carbon Dioxide / Q000378:metabolism; D000697:Central Nervous System Stimulants / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D000860:Hypoxia / Q000503:physiopathology; D008297:Male; D010991:Plethysmography; D011280:Pregnanolone / Q000494:pharmacology*; D011374:Progesterone / Q000494:pharmacology*; D011372:Progestins / Q000494:pharmacology; D051381:Rats; D012119:Respiration / Q000187:drug effects*; D012727:Sex Characteristics
chemical_list: D000777:Anesthetics; D000697:Central Nervous System Stimulants; D004338:Drug Combinations; D011372:Progestins; D002245:Carbon Dioxide; D002110:Caffeine; D011374:Progesterone; D011280:Pregnanolone